What is retatrutide and how does it work?

What is retatrutide?

Retatrutide is an investigational medicine being developed by Eli Lilly for weight management and related metabolic conditions. Like Wegovy and Mounjaro, it is a once-weekly injection that works on the body's gut-hormone signalling — but it goes one step further in how many of those signals it uses.

You will see the same compound described several ways online — a "triple agonist", a "triple G", an "incretin mimetic", or simply "reta". They all refer to the same thing: a synthetic peptide designed to activate three of the body's metabolic hormone receptors at once. The nickname culture matters only because it is how grey-market sellers make an investigational compound sound like an established product; the regulatory facts below are unaffected by branding.

The crucial word is investigational. Retatrutide is still in large phase 3 clinical trials and has not been approved by any regulator: not the MHRA in the UK, not the EMA in Europe, and not the FDA in the United States. That means it cannot legally be prescribed, sold or supplied for use in the UK outside a regulated clinical trial. See our retatrutide UK approval timeline for where things currently stand.

The "triple agonist" idea

The medicines in this family mimic natural gut hormones that regulate appetite and blood sugar. Semaglutide (the active ingredient in Wegovy) acts on one receptor — GLP-1. Tirzepatide (Mounjaro) acts on two — GLP-1 and GIP. Retatrutide acts on three: GLP-1, GIP and the glucagon receptor.

The first two signals reduce appetite, slow stomach emptying and improve the body's insulin response — the familiar GLP-1 effects we explain in our guide to how GLP-1 receptor agonists work. The third, glucagon, is the novel part: it is thought to increase the body's energy expenditure, so the medicine works on both sides of the energy equation — appetite in, energy out.

What have the trials shown so far?

Published phase 2 results (New England Journal of Medicine, 2023) reported average weight loss of around 24% of body weight at the highest dose after 48 weeks — larger average reductions than reported in trials of any currently licensed weight-loss medicine. Those results are why retatrutide attracts so much attention online.

Phase 2 findings are not the finished picture, though. The larger phase 3 programme (known as TRIUMPH) is still running, and it is designed to answer the questions that decide approval: how the medicine performs across bigger, more varied populations, how durable the results are, and what the full safety profile looks like. Regulators will only license retatrutide once that evidence is in.

What about side effects?

In trials so far, the side-effect pattern looks like the rest of the class: predominantly gastrointestinal — nausea, vomiting, constipation and diarrhoea — most noticeable while the dose is being stepped up, and generally mild to moderate. Our guide to GLP-1 side effects explains how these effects are managed with licensed treatments; the same principles are being applied in the retatrutide trials.

Because the medicine is still investigational, its long-term safety profile is genuinely unknown — that is precisely what phase 3 exists to establish.

How retatrutide is taken in the trials

In the trial programme, retatrutide is a once-weekly subcutaneous injection — the same format as the licensed medicines in this class. Treatment starts at a low dose and is escalated stepwise over several months, a schedule designed to let the body adapt and to keep gastrointestinal side effects manageable. Participants receive it alongside structured dietary and activity support, and with regular monitoring of weight, blood markers and side effects.

Beyond weight management, retatrutide is also being studied in type 2 diabetes and related metabolic conditions, where the same three-hormone mechanism is expected to improve blood-glucose control. Results from those studies will shape what any eventual licence covers — regulators approve medicines for specific, evidenced uses, not as general-purpose metabolic tools.

Can you get retatrutide in the UK?

No — not legally, outside a clinical trial. Anything sold online as "retatrutide" is an unlicensed product with no quality assurance, and we cover the risks in detail in our guide to where you can get retatrutide in the UK.

If the science behind retatrutide appeals to you, the practical takeaway is that the same hormone-based approach is already available in licensed form. Wegovy and Mounjaro are regulated, quality-assured and prescribed with clinical oversight — and our weight-management guides cover them thoroughly. A clinician can advise which, if any, fits your circumstances.

Who would retatrutide be for, if approved?

Licences follow trial populations. Retatrutide's weight-management trials enrolled adults with obesity (a BMI of 30 or above) or overweight with weight-related health conditions, and its diabetes trials enrolled adults with type 2 diabetes needing better glycaemic control — so any eventual UK licence would most likely mirror the shape of the existing GLP-1 licences, with prescribing alongside diet and activity changes and under clinical supervision.

It is also reasonable to expect the same eligibility infrastructure: an assessment of BMI, comorbidities, medical history and current medicines before prescribing, and NICE appraisal before any NHS availability. In other words, even in the version of the future where retatrutide is approved, the route to it runs through exactly the kind of clinical consultation that already exists for today's licensed treatments.

The bigger picture: a fast-moving field

Retatrutide is one entry in an unusually active pipeline. The last three years have brought a licensed dual agonist (Mounjaro), the first oral small-molecule GLP-1 (Foundayo, approved in the UK this month), and multiple further candidates in late-stage trials across the industry. For patients, the practical meaning is encouraging: options are multiplying, formats are diversifying, and waiting for one specific investigational compound makes less sense than it ever has. The right treatment conversation is about what fits your health now — not about which trial readout to gamble on.

Questions worth asking a clinician

If this article brought you here via retatrutide searches, these are the productive questions to take into a consultation: Am I eligible for a licensed weight-management medicine, and which fits my history? What results should I realistically expect, and over what timescale? How will side effects be managed during dose escalation? What happens if a first treatment does not suit me? A UK-registered clinician can answer all of these against your actual health picture — which no trial average, and no anonymous seller, can do.